Endo International's $1.45B Settlement Over Misbranding Opioid Charge
Thursday, 29 February 2024, 18:46
Endo International Settles $1.45B Misbranding Opioid Charge with Feds
Endo International has reached an agreement to pay over $1.45 billion to settle a misdemeanor misbranding violation related to its opioid Opana ER. This settlement reflects a significant legal and financial development for the company.
Key Points:
- Amount: Over $1.45 billion
- Violation Type: Misdemeanor misbranding
- Product: Opana ER
The resolution underscores the importance of compliance and responsible corporate conduct in the pharmaceutical sector. Endo International aims to address the repercussions of the opioid crisis while moving forward with its operations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.